OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Milei Threatens Falkland Oil Firms With Sanctions 
Xiaomi Shares Jump on Europe EV Expansion Plan 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Add as a preferred source on Google
AMES, Iowa, Feb. 16, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and year end 2017 financial results on Thursday, March 1, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results and to give an update on clinical and business development activities.
NewLink Genetics' senior management team will host the conference call, which will be open to all listeners. There will also be a question and answer session following the prepared remarks.
Access to the live call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call. The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/8rng5oig. A replay of the call will be available for two weeks from the date of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 9466627.
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod, the company’s leading IDO inhibitor, is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies. For more information, visit www.newlinkgenetics.com, and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
(515) 598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
